<DOC>
	<DOCNO>NCT02177318</DOCNO>
	<brief_summary>To collect post-marketing safety effectiveness information use Tiotropium Inhalation Capsules ( 18 Î¼g ) patient chronic obstructive pulmonary disease daily clinical setting</brief_summary>
	<brief_title>Tiotropium Treatment Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients COPD There exclusion criterion , post marketing study ( PMS ) observational survey condition normal clinical practice</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>